Medscape is available in 5 Language Editions – Choose your Edition here.


Antiadrenal Antibody 

  • Author: Alina G Sofronescu, PhD; Chief Editor: Eric B Staros, MD  more...
Updated: Mar 02, 2015

Reference Range

The reference range for this assay is < 1 U/mL.



Positive results from this assay (ie, ≥1 U/mL) indicate the presence of adrenal cortex autoantibodies in serum, a finding that is consistent with Addison disease.[1]


Collection and Panels

Specifics for the handling of specimens are as follows:

  • Container - Plain red or SST
  • Preparation - Transfer 1 mL serum to transport tube
  • Temperature for storage and transport - Refrigerated
  • Hemolyzed specimens are unacceptable
  • Stability (from collection to initiation of testing [after separation from cells]) - Ambient temperature, unacceptable; refrigerated, 1 week; frozen, 6 months

Measurement of 21-hydroxylase-specific antibody

The 21-hydroxylase–specific antibodies are quantitated in the clinical laboratory by using radioimmunoassay (RIA). The calibrators, controls, and patient specimens are incubated overnight with iodine I125 –labeled 21-hydroxylase. Specific antibodies, if present, bind to the 21-hydroxylase during this time. After overnight incubation, protein A is added to precipitate the antibodies present; the assay tubes are then centrifuged and the pellet is analyzed. The amount of radioactivity in the pellet is directly proportional to the amount of antibody contained in the specimen.




Steroid synthesis is a very complex process that takes place in the adrenal glands and gonads. The pathway involves multiple enzymes and multiple enzymatic reactions. Steroid synthesis starts from cholesterol (low-density lipoprotein cholesterol [LDL-C]) and leads to production of three classes of specific adrenocortical steroid hormones: glucocorticoids, mineralocorticoids, and sex steroids. See the figure below.

Steroid hormones pathway. Steroid hormones pathway.

Deletions or mutations of the genes encoding the enzymes involved in the synthesis or impaired function of the enzymes involved in the steroid hormones pathway (eg, autoantibodies) leads to deficiency of different hormones.[2]

In autoimmune adrenal disease, serum antibodies against several steroidogenic enzymes—including P450scc (CYP11A1, side-chain cleavage enzyme), P450c17 (CYP17, 17-alpha-hydroxylase), and P450c21 (CYP21A2, 21-hydroxylase)—are present. These enzymes play a role in side-chain cleavage and hydroxylation of steroids. Of these, most commonly, patients with autoimmune adrenal disease have autoantibodies directed against the microsomal 21-hydroxylase. Therefore, laboratory assessment of these types of antibodies is clinically very useful for the diagnosis of autoimmune adrenal disease (eg, Addison disease).[3, 4] The presence of antiadrenal autoantibodies in serum is characteristic of autoimmune Addison disease (ie, chronic primary adrenal insufficiency, resulting from autoimmune destruction of the adrenal cortex).[1, 5]


[#Background]Antibodies to 21-hydroxylase are markers of autoimmune Addison disease, whether this condition is occurring alone or in conjunction with other autoimmune endocrine diseases as part of type I or type II autoimmune polyglandular syndrome (APS). These antibodies may be present even before any reduction in endocrine function is apparent. Patients with autoimmune adrenal insufficiency commonly have antibodies against other endocrine glands, whereas healthy patients rarely do. More than 50% of these patients have high serum antithyroid peroxidase antibody levels, and nearly 50% have overt hypothyroidism. Many more of these patients exhibit subclinical hypothyroidism (evidenced by elevated thyroid-stimulating hormone [TSH] and normal thyroxine concentrations) and are at risk for subsequent development of overt hypothyroidism (Schmidt syndrome).[6, 7]

Autoimmune adrenal disease can be conveniently divided into phases. Initially, the adrenals may be enlarged, and extensive lymphocytic infiltration may be noted. In long-standing disease, however, the glands are small and may be hard to find. A thickened, fibrotic capsule is observed, with complete destruction of the cortex (although a few small clusters of adrenocortical cells surrounded by lymphocytes may remain) and relative sparing of the medulla. Only after at least 90% of the cortex has been destroyed does adrenal insufficiency clinically manifest.


In patients with normal adrenal function who have other autoimmune endocrine diseases, the prevalence of antiadrenal autoantibodies in serum is low (2%), the exception being those with hypoparathyroidism, in whom the figure is substantially higher (16%).[8, 9]

Autoimmune adrenal insufficiency may be either familial or nonfamilial (acquired); when occurring alone, rather than as part of APS type I or II, it is somewhat less likely to be familial. About half the patients who have adrenal insufficiency as part of APS type I or II have affected family members, compared with only about one third of patients who have autoimmune adrenal insufficiency alone.

As the enzyme 21-hydroxylase is involved in the metabolism of both mineralocorticoids (aldosterone) and glucocorticoids (cortisol) (see figure above), impaired 21-hydroxylase function due to the binding antibodies can lead to deficiency in both of these types of hormones. On the other hand, patients have an elevated serum concentration of 17-α hydroxyprogesterone, progesterone, 17-α hydroxypregnenolone, and pregnenolone. Adrenal androgens, DHEA-S, DHEA, and 3-α androstanediol (a metabolite of androgens) are also often elevated in these patients.

Women might present with hirsutism (mild), polycystic ovarian syndrome (PCOS) and primary and secondary amenorrhea. The adrenals might become hyperplasic and the patient might have low serum sodium and chloride levels and hyperkalemia (salt-wasting forms).[2]

Contributor Information and Disclosures

Alina G Sofronescu, PhD Assistant Professor, Board Certified Clinical Chemist, Technical Director of Clinical Chemistry Laboratory, Department of Pathology and Microbiology, University of Nebraska Medical Center

Alina G Sofronescu, PhD is a member of the following medical societies: American Association for Clinical Chemistry, Canadian Society of Clinical Chemists

Disclosure: Nothing to disclose.

Chief Editor

Eric B Staros, MD Associate Professor of Pathology, St Louis University School of Medicine; Director of Clinical Laboratories, Director of Cytopathology, Department of Pathology, St Louis University Hospital

Eric B Staros, MD is a member of the following medical societies: American Medical Association, American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology

Disclosure: Nothing to disclose.

  1. Nerup J. Addison's disease--serological studies. Acta Endocrinol (Copenh). 1974 May. 76(1):142-58. [Medline].

  2. Burtis CA, Ashwood ER, Bruns DE. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 4th ed. Philadelphia, Pa: Saunders; 2006.

  3. Dalla Costa M, Bonanni G, Masiero S, Faggian D, Chen S, Furmaniak J, et al. Gonadal function in males with autoimmune Addison's disease and autoantibodies to steroidogenic enzymes. Clin Exp Immunol. 2014 Jun. 176(3):373-9. [Medline]. [Full Text].

  4. Horn MA, Erichsen MM, Wolff AS, Månsson JE, Husebye ES, Tallaksen CM, et al. Screening for X-linked adrenoleukodystrophy among adult men with Addison's disease. Clin Endocrinol (Oxf). 2013 Sep. 79(3):316-20. [Medline].

  5. Husebye ES, Allolio B, Arlt W, Badenhoop K, Bensing S, Betterle C, et al. Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J Intern Med. 2014 Feb. 275(2):104-15. [Medline].

  6. Boscaro M, Betterle C, Sonino N, Volpato M, Paoletta A, Fallo F. Early adrenal hypofunction in patients with organ-specific autoantibodies and no clinical adrenal insufficiency. J Clin Endocrinol Metab. 1994 Aug. 79(2):452-5. [Medline].

  7. McHardy-Young S, Lessof MH, Maisey MN. Serum TSH and thyroid antibody studies in Addison's disease. Clin Endocrinol (Oxf). 1972 Jan. 1(1):45-56. [Medline].

  8. Irvine WJ, Barnes EW. Addison's disease, ovarian failure and hypoparathyroidism. Clin Endocrinol Metab. 1975. 4:379.

  9. Blizzard RM, Chee D, Davis W. The incidence of parathyroid and other antibodies in the sera of patients with idiopathic hypoparathyroidism. Clin Exp Immunol. 1966 Apr. 1(2):119-28. [Medline]. [Full Text].

Steroid hormones pathway.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.